scholarly article | Q13442814 |
P356 | DOI | 10.1161/CIRCHEARTFAILURE.113.000284 |
P698 | PubMed publication ID | 24281134 |
P50 | author | Piotr Ponikowski | Q22114836 |
Gad Cotter | Q37623977 | ||
Beth A. Davison | Q39274037 | ||
Marco Metra | Q39274051 | ||
John Cleland | Q44931654 | ||
Karen Chiswell | Q64683299 | ||
Christopher M O'Connor | Q64689171 | ||
Susanna R Stevens | Q64856812 | ||
Michael M Givertz | Q90393574 | ||
John R Teerlink | Q90422543 | ||
Adriaan A Voors | Q91537232 | ||
Barry M. Massie | Q114321736 | ||
George A. Mansoor | Q114429076 | ||
P2093 | author name string | Mona Fiuzat | |
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | heart failure | Q181754 |
placebo | Q269829 | ||
acute decompensated heart failure | Q4677930 | ||
P304 | page(s) | 76-87 | |
P577 | publication date | 2013-11-26 | |
P1433 | published in | Circulation: Heart Failure | Q2865806 |
P1476 | title | Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospital | |
P478 | volume | 7 |
Q57422643 | Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial |
Q30234708 | Addressing the Heterogeneity of Heart Failure in Future Randomized Trials. |
Q38262814 | Adenosine, type 1 receptors: role in proximal tubule Na+ reabsorption |
Q26800965 | Assessment and prevalence of pulmonary oedema in contemporary acute heart failure trials: a systematic review |
Q64945828 | Association of admission vs. nadir serum albumin concentration with short-term treatment outcomes in patients with acute heart failure. |
Q88160619 | Associations between volume status and circulating microRNAs in acute heart failure |
Q38626779 | Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure |
Q92666278 | Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score |
Q91662964 | Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission |
Q88035084 | Combined use of lung ultrasound, B-type natriuretic peptide, and echocardiography for outcome prediction in patients with acute HFrEF and HFpEF |
Q38960401 | Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial |
Q47279019 | Critical Appraisal of Multivariable Prognostic Scores in Heart Failure: Development, Validation and Clinical Utility |
Q38201299 | Decision-making under uncertainty in advanced heart failure |
Q36932609 | Depression and Multiple Rehospitalizations in Patients With Heart Failure |
Q40313672 | Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure |
Q35810391 | Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF. |
Q39338234 | Dynamic changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic heart failure: a systematic review |
Q44129824 | Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial |
Q38851058 | Echocardiographic predictors of outcome in acute heart failure patients in sub-Saharan Africa: insights from THESUS-HF |
Q38705811 | Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial : Differential Response in Acute Heart Failure |
Q94487073 | Impact of diabetes mellitus on mortality in patients with acute heart failure: a prospective cohort study |
Q104258992 | Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis |
Q46465745 | In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry |
Q58554416 | Mode of presentation and mortality amongst patients hospitalized with heart failure? A report from the First Euro Heart Failure Survey |
Q51226890 | Non classical Monocytes Levels, Increased by Subcutaneous Fat-Secretome, Are Associated with Less Rehospitalization after Heart Failure Admission. |
Q41074638 | Optimizing clinical use of biomarkers in high-risk acute heart failure patients |
Q38560109 | Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality |
Q89903377 | Pharmacological interventions for heart failure in people with chronic kidney disease |
Q40126626 | Plasma Neutrophil Gelatinase-Associated Lipocalin and Predicting Clinically Relevant Worsening Renal Function in Acute Heart Failure |
Q40311889 | Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure |
Q41174254 | Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome |
Q37624195 | Precipitating Factors for Acute Heart Failure Hospitalization and Long-Term Survival |
Q58788721 | Prediction of readmissions and mortality in patients with heart failure: lessons from the IMPEDANCE-HF extended trial |
Q47580229 | Provider Connectedness to Other Providers Reduces Risk of Readmission After Hospitalization for Heart Failure |
Q59637210 | Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF) |
Q99413029 | Suppression Tumorigenicity 2 (ST2) Turbidimetric Immunoassay Compared to Enzyme-Linked Immunosorbent Assay in Predicting Survival in Heart Failure Patients with Reduced Ejection Fraction |
Q64279311 | The role of intestinal microbiota in cardiovascular disease |
Q88915069 | Validation of U.S. mortality prediction models for hospitalized heart failure in the United Kingdom and Japan |
Q26771479 | What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold? |
Search more.